Document:

ASSET PURCHASE AGREEMENT

Apptasmic Theme Park Wait Time Apps

 

This Asset Purchase Agreement, hereinafter referred to as "Agreement",
is executed on April 2nd, 2013 by Catalina Ventures Inc. having its principal office of business at 1701
W. Northwest Highway, Grapevine, Texas 76051, hereinafter referred to as "Seller," and AppYea
Inc., having its principal office of business at 777 Main Street, Suite 600, Fort Worth, TX 76102 hereinafter
referred to as "Buyer."

 

WITNESSETH:

 

WHEREAS, Seller is the owner of the Asset; the
brand name Apptasmic Theme Park Wait Time Apps and all associated intellectual properties,
included but not limited to websites, logos, mobile application, software and/or source codes and /or algorithms.

 

WHEREAS, Seller desires to sell all mobile apps and
Buyer agrees to purchase all mobile apps from Seller.

 

NOW, THEREFORE, for and in consideration of the mutual covenants
and promises hereinafter contained, the Seller agrees to sell, and the Buyer agrees to buy the mobile apps upon the following terms
and conditions.

 

A. Subject Matter

 

1. Description of Brand Apptasmic Theme Park Wait
Time Apps Mobile Apps 

 

The Mobile Apps includes the following properties:

 

The Inventory, which includes the all intellectual
properties related to the mobile apps are to be sold and purchased under this Agreement.

 

Assets owned by seller as
of the date hereof and as of the Closing Date:

 

		1.	All the current mobile applications, software properties, where applicable, for the applications
listed below:

 

Wait times at Disney World Orland

Wait times for Universal Studios Orland

Free Wait times at Disney World

Free Wait times at Universal Studios

Wait Times, Hours, Maps and Dining by Apptasmic.com
at Disney World & Universal Studios Orlando

 

		2.	Complete list of apps is visible in the iOs app store here: 
	 	 	https://itunes.apple.com/us/artist/disney-map-appsllc/id457118832

 

    	 

    	 

    

 

		3.	All outstanding accounts receivable as of the closing
date. (Additional screenshot in exhibit “C”)

 

2. Purchase Price and Method of Payment

 

Buyer shall pay and Seller shall accept the purchase price for
Mobile as follows:

 

Consideration

 

As total consideration for the purchase and sale of the Mobile
apps (as described above), the Buyer shall pay to the Seller the sum of $52,176.22, and such total consideration
to be referred to in this Agreement as the "Purchase Price."

 

Payment:

 

		(A)	The sum of $22,176.22 shall be delivered to
Seller upon Buyer's execution of this Agreement. Subject to the following conditions the Buyer shall make final payment for the
property at closing in the total amount of $22,176.22.

(The amounts that Purchaser will receive from
Apple post closing are: $1,143.02 on April 4 payment and $1,033.64 coming for the following pay date (calculated to March 22)).

 

		(B)	Plus $15,000.00 of the Purchase Price (“Earn Out”) will be paid directly from Purchaser
to Seller as twenty (20) percent of Net Revenue until the maximum of $15,000.00 is paid. Earn Out payments to be calculated from
Closing Date and on, with monthly payments due within 15 days of receipt of revenue, and payments starting on May 15, 2013.
Net Revenue to be defined as all combined revenue generated from the Company and Assets less any Apple fees.; and

 

		(C)	Plus Remaining balance to be issued in the form of a convertible promissory note payable in the
amount of $15,000.00 (exhibit “D”)

 

Allocation

The Purchase Price shall be allocated for tax purposes as follows:

 

Asset PurchasedFair Market Value

All Property Conveyed$52,176.22

 

3. Closing

 

Time and Place of Closing

 

Closing is the date and time at which parties agree
to finalize this transaction. The closing date is designated as the week of April 2nd, 2013, provided there are no unforeseen
delays. Time is of the essence, and in no event shall closing be later than 7 calendar days after designated closing date, unless
an extension is agreed upon in writing between the Buyer and the Seller.

 

    	 

    	 

    

 

At Closing Seller shall deliver
to the Buyer a final, executed Bill of Sale transferring to Buyer all of the assets sold hereunder, free and clear of any and all
liens, encumbrances, security interests, debts or taxes of any nature whatsoever.

 

B. Representations and Warranties of
Seller

 

Authority relative to this Agreement. Except
as otherwise stated herein, the Seller has full power and authority to execute this Agreement and carry out the transactions contemplated
by it. No further action is necessary by the Seller to make this Agreement valid and binding upon Seller and enforceable against
it in accordance with the terms hereof, or to carry out the actions contemplated hereby. The execution, delivery, and performance
of this Agreement by the Seller will not constitute:

 

(i)a breach or a violation
of its Corporation's Certificate of Incorporation, by-laws, or of any law, agreement, indenture, deed of trust, mortgage, loan
agreement or other instrument to which it is a party, or by which it is bound;

 

(ii)a violation of any
order, judgment or decree to which it is a party or by which its assets or properties is bound or affected; or

 

(iii)result in the creation
of any lien, charge or encumbrance upon its assets or properties except as stated herein.

 

Properties. The Seller has good and merchantable
title to all of its properties and assets as defined herein. At Closing, such properties and assets will be subject to no mortgage,
pledge, lien, conditional sales agreement, security agreement, encumbrance or charge, secured or unsecured, except for those taxes
which shall be pro-rated as of the date of Closing. Seller has or will pay all debts incurred by it up to the date of occupancy
by Buyer including all employee compensation and utilities.

 

Compliance with Applicable
Laws. None of the Seller's actions in transferring good and merchantable title to those assets and properties set out in herein
are prohibited by or have violated or will violate any law in effect on the date of this Agreement or on the date of closing.

 

Documents for Review. The Seller's Documents
for Review enumerated in Exhibit "A" attached hereto and made a part hereof are true, authentic, and correct copies of
the originals, or as appropriate the originals themselves, and no alterations and modifications thereof have been made.

 

C. Representations and Warranties by
both Buyer and Seller

 

Warrants

Buyer and Seller hereby represent and warrant that there
has been no act or omission by Buyer or Seller which would give rise to any valid claim against any of the parties hereto for
a brokerage commission, finder's fee, or other like payment in connection with the transactions contemplated hereby.

 

    	 

    	 

    

 

Payment of Costs and Expenses

Except as expressly provided to the contrary in this
Agreement, each party shall pay all of its own costs and expenses incurred with respect to the negotiation, execution and delivery
of this Agreement and the exhibits hereto.

 

Indemnification

Buyer shall indemnify and hold
Seller harmless from any and all liabilities and obligations arising from Buyer's operation or use of the Assets after the Closing.
Similarly, Seller shall indemnify and hold Buyer harmless from any and all liabilities and obligations arising from Seller's operation
or use of the Assets prior to the Closing.

 

Default

After execution of this Agreement by the parties, if either
party fails to perform its respective obligations, or breaches a warranty or covenant, that would constitute a default. The defaulting
party shall cure the default with in 7 days of notice by the other party. In the event of a failure to cure such default by either
party within the stipulated time, Seller or Buyer shall have the right to cancel this transaction and/or sue for damages in addition
to any other relief provided under this Agreement. In a suit for default, the prevailing party shall recover reasonable attorney
fees.

 

Survival of Representations and Warranties

Each of the parties to this Agreement covenants and
agrees that their respective representations, warranties, covenants, statements, and agreements contained in this Agreement shall
survive the Closing Date. Except the exhibits hereto or the documents and papers delivered by Seller to Buyer in connection with
the Agreement herewith, there are no other agreements, representations, warranties, or covenants by or among the parties hereto
with respect to the subject matter hereof.

 

Cooperation

Both Seller and Buyer agrees to cooperate fully with
each other and to execute such further instruments, documents and agreements and to give such further written assurances, as may
be reasonably requested by the parties, to better evidence and consummate the transactions described herein and contemplated hereby,
and to carry into effect the intents and purposes of this Agreement.

 

Confidentiality

Both Seller and Buyer shall not divulge, communicate, or use
to the detriment of the other or for the benefit of any other person or persons, or misuse in any way, any of Seller's confidential
information discovered by or disclosed to Seller or Buyer as a result of the delivery, execution or performance of this Agreement.

 

    	 

    	 

    

 

D. Transactions prior to Closing

 

Conduct of Seller's Assets until Closing. Except as Buyer
may otherwise consent in writing prior to the Closing Date, Seller will not enter into any transaction, take any action, or fail
to take any action which would result in or could reasonably be expected to result in or cause any of the representations and warranties
of Seller contained in this Agreement to be void, invalid, or false on the Closing Date.

 

Satisfactions. Seller shall deliver to Buyer
on the Closing Date a satisfaction of any encumbrance or lien on the Assets, satisfactory in form and substance to the Buyer, indicating
that the then outstanding unpaid principal balance of any promissory note secured thereby has been paid in full prior to or simultaneously
with the closing.

 

Advice of Changes. Between the date hereof
and the Closing Date, Seller will promptly advise Buyer in writing of any fact which, if existing or known at the date hereof,
would have been required to be set forth herein or disclosed pursuant to this Agreement.

 

Documents. Seller shall deliver to Buyer at
closing such documents which are in Buyer's sole discretion and necessary to fully satisfy the objectives of this Agreement in
content and form.

 

E. General Provisions

 

Waivers

No action taken pursuant to this Agreement including
any investigation by or on behalf of any party shall be deemed to constitute a waiver by the party taking such action of compliance
with any representation, warranty, covenant or agreement contained herein or therein and in any documents delivered in connection
herewith or therewith. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed
as a waiver of any subsequent breach.

 

Notices

All notices, requests, demands and other communications
which are required or may be given under this Agreement shall be in writing and shall be deemed to have been duly given if delivered
or mailed, first class mail, postage prepaid to Seller, Buyer, or to such other address as such party shall have specified by notice
in writing to the other party.

 

Sections and Other Headings

The section and other headings contained in this
Agreement are for reference purposes only and shall not affect the meaning or interpretations of this Agreement.

 

Governing Law

This agreement and all transactions
contemplated hereby shall be governed by and construed and enforced in accordance with the laws of Nevada. Any dispute
arising under this contract shall be resolved under the commercial arbitration rules of the American Arbitration Association.
In the event that arbitration or litigation results from or arises out of this Agreement or the performance thereof, the
parties agree to reimburse the prevailing party's reasonable attorney's fees, court costs, and all other expenses, whether or
not taxable by the court as costs, in addition to any other relief to which the prevailing party may be entitled.

 

    	 

    	 

    

 

Conditions Precedent

If the obligations and responsibility of either party
are not fulfilled by the appropriate dates thereof, then this Agreement shall be deemed null and void and any deposits paid at
said time shall be returned to the Buyer forthwith.

 

Time is of the Essence

Time and timely performance are of the essence in
this contract and of the covenants and provisions hereunder.

 

Successors and Assigns

This Agreement may not be assigned without the prior
written consent of the parties hereto. Rights and obligations created by this contract shall be binding upon and inure to the benefit
of the parties hereto, their successors and assigns. Whenever used, the singular number shall include the plural, the plural the
singular, and the use of any gender shall include all genders.

 

Contractual Procedures

Unless specifically disallowed by law, service of
process in any litigation that arise hereunder may be obtained through certified mail, return receipt requested; the parties hereto
waiving any and all rights they may have to object to the method by which service was perfected.

 

Extraordinary Remedies

To the extent cognizable at law, in the event of breach the
parties hereto may obtain injunctive relief in addition to any and all other remedies available thereto regardless of whether the
injured party can demonstrate that no adequate remedy exists at law.

 

Entire Agreement

This Contract contains the entire agreement of the
parties, and there are no other promises or conditions in any other agreement whether oral or written concerning the subject matter
of this Contract. This Contract supersedes any prior written or oral agreements between the parties.

 

Severability

If any provision of this Contract will be held to be invalid
or unenforceable for any reason, the remaining provisions will continue to be valid and enforceable. If a court finds that any
provision of this Contract is invalid or unenforceable, but that by limiting such provision it would become valid and enforceable,
then such provision will be deemed to be written, construed, and enforced as so limited.

 

Amendments

This Contract may be modified or amended in writing,
if the writing is signed by the party obligated under the amendment.

 

    	 

    	 

    

 

Initials and Exhibits

This Contract
shall not be valid and enforceable unless it is properly executed by Buyer and Seller and their initials affixed to each page of
the exhibits attached hereto and made a part hereof.

 

IN WITNESS WHEREOF, this Agreement
has been executed by each of the individual parties hereto all on the date and year first above written.

 

BUSINESS:

 

		 	04/02/2013
	Catalina Ventures Inc.	 	Date

 

BUYER:

		 	04/02/2013
	AppYea Inc.	 	Date
	Mr. J.D. Williams	 	 

 

    	 

    	 

    

 

Exhibit "A"

Documents for Review

 

Software properties for developed mobile apps
delivered

 

		 	04/02/2013
	Catalina Ventures Inc.	 	Date

  

		 	04/02/2013
	AppYea Inc.	 	Date
	Mr. J.D. Williams	 	 

 

    	 

    	 

    

 

Exhibit "B"

DISBURSEMENT REQUEST

 

APPYEA Inc.and Catalina
Ventures Inc. hereby request disbursement of funds in the amount and manner described below.

 

	Please disburse to:	Catalina Ventures Inc
	 	 
	Amount to disburse:	$22,176.22
	Form of distribution:	Certified Funds
	Payee:	Catalina Ventures Inc.

 

	Please disburse to:	 
	Amount to disburse:	$22,176.22
	Form of distribution	Certified Funds
	Name	Catalina Ventures Inc.
	Address	1701 W. Northwest Hwy, Grapevine TX 76054
	Promissory Convertible Note Amount:	$15,000.00
	Term of Note:	12 Months
	Interest:	12%

 

	 	 	 	Total: $37,176.22
	APPYEA INC.	 	 	 
		 	 	 
	By:  	 	 	Dated: 04/02/2013 	 
	 	Name: JD Williams	 	 	 
	 	Title: President/Director	 	 	 
	 	 	 	 
	Catalina Ventures Inc.	 	 	 
		 	 	 
	By:	 	 	Dated: 04/02/2013 	 
	 	Name: Scott ONeal	 	 	 
	 	Title: Director	 	 	 

 

    	 

    	 

    

 

Exhibit "C"

Screen Shots of APPs

 

App Rankings:

 

Apptasmic is currently ranked
#3 in it’s genre with 3 top ranking apps within the top 25 with no marketing push.

 

	·	Disney/Universal combo app	#16	Dec 29 2011
	·	Disney Paid app	#23	Feb 8. 2012
	·	Universal Paid app	#25	Dec 28 2011
	·	Disney Wait app	#72	Aug 2 2012
	·	Universal Wait app	#61	Aug 5 2012
	·	Disney Free app	#111	Jul. 6 2012
	·	Universal Free app	#102	Aug 2 2012

 

    	 

    	 

    

 

Exhibit “D”

 

PROMISSARRY
NOTE

 

NEITHER THE ISSUANCE NOR SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES

INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,

AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,

TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE

SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL

SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT

REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.

NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE

MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

	Amount $15,000.00	Date: April 2nd, 2013

 

CONVERTIBLE PROMISARRY NOTE 

 

FOR VALUE RECEIVED, APPYEA INC.,
a South Dakota corporation (hereinafter called the "Borrower"), hereby promises to pay to the order of
CATALINA VENTURES INC., a Nevada corporation, or registered assigns (the "Holder") the sum of $15,000.00
together with any interest as set forth herein, on March 31st, 2014 (the "Maturity Date"), and to pay interest
on the unpaid principal balance hereof at the rate of twelve percent (12%) (the "Interest Rate") per annum from the date
hereof (the "Issue Date") until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment
or otherwise.

 

ARTICLE I

 

GENERAL PROVISIONS

 

1.1DEBT. The
Borrower agrees to pay the Holder Fifteen Thousand US Dollars ($15,000)

 

1.2Interest Rate. Interest shall accrue on the outstanding
balance under this Note at the rate of 12% per year.

 

1.3Payments. Outstanding
principal and interest are due on the date of Maturity. Interest is due and payable on the 1st day of each
calendar month. The Borrower has the right to prepay any portion or the entire outstanding balance at any time; or to
convert any portion into the shares of Company’s common stock in accordance with conditions set in Section 2.1.

 

1.4Maturity
Date. Subject to the right of the Holder with respect to its conversion rights hereunder, all principal with interest
accruing thereon is otherwise due on March 31st, 2014 (the "Maturity Date").

 

ARTICLE II

CONVERSION RIGHTS

 

2.1.Holder’s Conversion
Rights. Subject to Section 2.2, the Holder shall have the right, at any time from the date of issuance of this Note, to
convert all or any portion of the then aggregate outstanding Principal Amount of this Note, into shares of Common Stock,
subject to the terms and conditions set forth in this Article II at a fifty percent (50%) (the “Discount and
Multiplier”) of the lowest closing bid price for the Company’s common stock during the twenty (20) trading days
immediately preceding a conversion date, as reported by Bloomberg LP (the “Closing Bid Price”) (“Initial
Conversion Price”); The Holder may exercise such right by delivery to the Borrower of a written Notice of Conversion
pursuant hereto.

 

    	 

    	 

    

 

ARTICLE III

 

A.Merger,
Sale of Assets, etc. If the Borrower at any time shall consolidate with or merge into or sell or convey all or substantially all
its assets to any other corporation, this Note, as to the unpaid principal portion thereof and accrued interest thereon, shall
thereafter be deemed to evidence the right to purchase such number and kind of shares or other securities and property as would
have been issuable or distributable on account of such consolidation, merger, sale or conveyance, upon or with respect to the securities
subject to the conversion or purchase right immediately prior to such consolidation, merger, sale or conveyance. The foregoing
provision shall similarly apply to successive transactions of a similar nature by any such successor or purchaser. Without limiting
the generality of the foregoing, the anti-dilution provisions of this Section shall apply to such securities of such successor
or purchaser after any such consolidation, merger, sale or conveyance.

 

B.Reclassification,
etc. If the Borrower at any time shall, by reclassification or otherwise, change the Common Stock into the same or a different
number of securities of any class or classes that may be issued or outstanding, this Note, as to the unpaid principal portion thereof
and accrued interest thereon, shall thereafter be deemed to evidence the right to purchase an adjusted number of such securities
and kind of securities as would have been issuable as the result of such change with respect to the Common Stock immediately prior
to such reclassification or other change.

 

C.Stock Splits, Combinations
and Dividends. If the shares of Common Stock are subdivided or combined into a greater or smaller number of shares of Common Stock,
or if a dividend is paid on the Common Stock in shares of Common Stock, the Conversion Price shall be proportionately reduced in
case of subdivision of shares or stock dividend or proportionately increased in the case of combination of shares, in each such
case by the ratio which the total number of shares of Common Stock outstanding immediately after such event bears to the total
number of shares of Common Stock outstanding immediately prior to such event..

 

(d)Whenever the Conversion Price is
adjusted pursuant to Section 2.1(c) above, the Borrower shall promptly mail to the Holder a notice setting forth the
Conversion Price after such adjustment and setting forth a statement of the facts requiring such adjustment.

 

2.2Method
of Conversion. This Note may be converted by the Holder in whole or in part as described in Section 2.1(a) hereof and the
Subscription Agreement. Upon partial conversion of this Note, a new Note containing the same date and provisions of this Note
shall, at the request of the Holder, be issued by the Borrower to the Holder for the principal balance of this Note and
interest which shall not have been converted or paid.

 

2.3Maximum Conversion. The Holder
shall not be entitled to convert on a Conversion Date that amount of the Note in connection with that number of shares of
Common Stock which would be in excess of the sum of (i) the number of shares of Common Stock beneficially owned by the Holder
and its affiliates on a Conversion Date, (ii) any Common Stock issuable in connection with the unconverted portion of the
Note, and (iii) the number of shares of Common Stock issuable upon the conversion of the Note with respect to which the
determination of this provision is being made on a Conversion Date, which would result in beneficial ownership by the Holder
and its affiliates of more than 4.99% of the outstanding shares of Common Stock of the Borrower on such Conversion Date. For
the purposes of the provision to the immediately preceding sentence, beneficial ownership shall be determined in accordance
with Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. Subject to the
foregoing, the Holder shall not be limited to aggregate conversions of only 4.99% and aggregate conversion by the Holder may
exceed 4.99%. The Holder shall have the authority and obligation to determine whether the restriction contained in this
Section 2.3 will limit any conversion hereunder and to the extent that the Holder determines that the limitation contained in
this Section applies, the determination of which portion of the Notes are convertible shall be the responsibility and
obligation of the Holder. The Holder may waive the conversion limitation described in this Section 2.3, in whole or in part,
upon and effective after 61 days prior written notice to the Borrower to increase such percentage to up to 9.99%.

 

    	 

    	 

    

 

EVENT OF DEFAULT

 

The occurrence
of any of the following events of default ("Event of Default") shall, at the option of the Holder hereof, make all sums
of principal and interest then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon
demand, without presentment, or grace period, all of which hereby are expressly waived, except as set forth below:

 

3.1Failure
to Pay Principal or Interest. The Borrower fails to pay any installment of principal, interest or other sum due under
this Note when due and such failure continues for a period often (10) days after the due date. The ten (10) day period
described in this Section 3.1 is the same ten (10) day period described in Section 1.1 hereof.

 

3.2Breach
of Covenant. The Borrower breaches any material covenant of this Note in any material respect and such breach, if subject
to cure, continues for a period of ten (10) business days after written notice to the Borrower from the Holder.

 

3.3Breach
of Representations and Warranties. Any material representation or warranty of the Borrower made herein, or in any
agreement, statement or certificate given in writing pursuant hereto or in connection therewith shall be false or misleading
in any material respect as of the date made and the Closing Date, and would otherwise have a material adverse effect on the
Borrower.

 

3.4Receiver
or Trustee. The Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the
appointment of a receiver or trustee for it or for a substantial part of its property or business; or such a receiver or
trustee shall otherwise be appointed.

 

3.5Judgments. Any
money judgment, writ or similar final process shall be entered or filed against Borrower or any of its property or
other assets for more than $100,000, and shall remain unvacated, unbonded or unstayed for a period of forty-five (45)
days.

 

3.6Bankruptcy. Bankruptcy,
insolvency, reorganization or liquidation proceedings or other proceedings or relief under any bankruptcy law or any law, or
the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against the
Borrower and if instituted against Borrower are not dismissed within 45 days of initiation.

 

3.7Non-Payment. A
default by the Borrower under any one or more obligations in an aggregate monetary amount in excess of $100,000 for more than
ten days after the due date, unless the Borrower is contesting the validity of such obligation in good faith.

 

3.8Failure
to Deliver Common Stock or Replacement Note. Borrower's failure to timely delivers Common Stock to the Holder pursuant to
and in the form required by this Note or, if required, a replacement Note.

 

3.9Reservation
Default. Failure by the Borrower to have reserved for issuance upon conversion of the Note the amount of Common stock as
set forth in this Note.

 

    	 

    	 

    

 

ARTICLE IV

HOLDER REPRESENTATIONS

 

Holder hereby represents and warrants to
and agrees with the Company only as to such Holder that:

 

(a)Information on Company. The
Holder has been furnished with or has had access at the EDGAR Website of the Commission to the Company's S-1 filings and all
periodic reports filed with the Commission thereafter not later than five days before the Closing Date (hereinafter referred
to as the "Reports"). In addition, the Holder has received in writing from the Company such other
information concerning its operations, financial condition and other matters as the Holder has requested in writing (such
other information is collectively, the "Other Written Information"), and considered all factors the Holder
deems material in deciding on the advisability of investing in the Securities.

 

(b)Information on Holder.
The Holder is, and will be at the time of the conversion of the Notes, an "accredited investor", as such term is defined
in Regulation D promulgated by the Commission under the 1933 Act, is experienced in investments and business matters, has made
investments of a speculative nature and has purchased securities of United States publicly-owned companies in private placements
in the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to
enable the Holder to utilize the information made available by the Company to evaluate the merits and risks of and to make an informed
investment decision with respect to the proposed purchase, which represents a speculative investment. The Holder has the authority
and is duly and legally qualified to purchase and own the Securities. The Holder is able to bear the risk of such investment for
an indefinite period and to afford a complete loss thereof. The information set forth on the signature page hereto regarding the
Holder is accurate.

 

(c)Purchase
of Notes. On the Closing Date, the Holder will purchase the Notes as principal for its own account for investment only and
not with a view toward, or for resale in connection with, the public sale or any distribution thereof, but Holder does not agree
to hold the Notes and Warrants for any minimum amount of time.

 

(d)Compliance with Securities
Act. The Holder understands and agrees that the Securities have not been registered under the 1933 Act or any applicable state
securities laws, by reason of their issuance in a transaction that does not require registration under the 1933 Act (based in part
on the accuracy of the representations and warranties of Holder contained herein), and that such Securities must be held indefinitely
unless a subsequent disposition is registered under the 1933 Act or any applicable state securities laws or is exempt from such
registration. Notwithstanding anything to the contrary contained in this Agreement, such Holder may transfer (without restriction
and without the need for an opinion of counsel) the Securities to its Affiliates (as defined below) provided that each such Affiliate
is an “accredited investor” under Regulation D and such Affiliate agrees to be bound by the terms and conditions of
this Agreement. For the purposes of this Agreement, an “Affiliate” of any person or entity means any other person
or entity directly or indirectly controlling, controlled by or under direct or indirect common control with such person or entity.
Affiliate when employed in connection with the Company includes each Subsidiary [as defined in Section 5(a)] of the Company. For
purposes of this definition, “control” means the power to direct the management and policies of such person
or firm, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise.

 

(e)Shares Legend.
The Shares shall bear the following or similar legend:

 

"THE SHARES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE SHARES MAY NOT BE SOLD, OFFERED
FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR ANY APPLICABLE
STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO EVCARCO, INC., THAT SUCH REGISTRATION IS NOT REQUIRED."

 

(f)Note Legend. The
Note shall bear the following legend:

 

    	 

    	 

    

 

"THIS NOTE AND THE
COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS
NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO EVCARCO, INC., THAT SUCH REGISTRATION IS NOT REQUIRED."

 

(g)Communication
of Offer. The offer to sell the Securities was directly communicated to the Holder by the Company. At no time was the Holder
presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement, or any other form
of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently with
such communicated offer.

 

(h)Authority; Enforceability.
This Agreement and other agreements delivered together with this Agreement or in connection herewith have been duly authorized,
executed and delivered by the Holder and are valid and binding agreements enforceable in accordance with their terms, subject to
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or
affecting creditors’ rights generally and to general principles of equity; and Holder has full corporate power and authority
necessary to enter into this Agreement and such other agreements and to perform its obligations hereunder and under all other agreements
entered into by the Holder relating hereto.

 

(i)No
Governmental Review. Holder understands that no United States federal or state agency or any other governmental or state
agency has passed on or made recommendations or endorsement of the Securities or the suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(j)Correctness of
Representations. Holder represents as that the foregoing representations and warranties are true and correct as of the date
hereof and, unless a Holder otherwise notifies the Company prior to the Closing Date shall be true and correct as of the Closing
Date.

 

(k)Survival. The
foregoing representations and warranties shall survive the Closing Date until three years after the Closing Date.

 

ARTICLE V

MISCELLANEOUS

 

5.1Failure or Indulgence Not
Waiver. No failure or delay on the part of Holder hereof in the exercise of any power, right or privilege hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or
further exercise thereof or of any other right, power or privilege. All rights and remedies existing hereunder are cumulative
to, and not exclusive of, any rights or remedies otherwise available.

 

5.2Notices. All
notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or
certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such
party shall have specified most recently by written notice. Any notice or other communication required or permitted to be
given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation
generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day
during normal business hours where such notice is to be received), or the first business day following such delivery (if
delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second
business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur.

 

    	 

    	 

    

 

5.3Amendment
Provision. The term "Note" and all reference thereto, as used throughout this instrument, shall mean this
instrument as originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

5.4Assignability. This
Note shall be binding upon the Borrower and its successors and assigns, and shall inure to the benefit of the Holder and its
successors and assigns.

 

5.5Cost
of Collection. If default is made in the payment of this Note, Borrower shall pay the Holder hereof reasonable costs of
collection, including reasonable attorneys' fees.

 

5.6Governing
Law. This Note shall be governed by and construed in accordance with the laws of the State of Texas. Any action brought
by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the
state courts of Texas or in the federal courts located in the state of Texas. Both parties and the individual signing this
Agreement on behalf of the Borrower agree to submit to the jurisdiction of such courts. The prevailing party shall be
entitled to recover from the other party its reasonable attorney's fees and costs.

 

5.7Maximum
Payments. Nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other
charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or
other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited
against amounts owed by the Borrower to the Holder

and thus refunded to the Borrower.

 

5.8Shareholder
Status. The Holder shall not have rights as a shareholder of the Borrower with respect to unconverted portions of this
Note. However, the Holder will have all the rights of a shareholder of the Borrower with respect to the shares of Common
Stock to be received by Holder after delivery by the Holder of a Conversion Notice to the Borrower.

 

IN WITNESS
WHEREOF, Borrower has caused this Note to be signed in its name by an authorized officer as of the 2nd day of April,
2013.

 

	 	 	APPYEA INC.
	 	 	 	 
	 	 	By:  	
	 	 	Name: JD Williams
	 	 	Title: President/Director
	 	 	 	 
	Catalina Ventures Inc.	 	 
	 	 	 	 
	By:  		 	 
	Name: Scott O’Neal	 	 
	Title: CIOWilbur H. Gantz

 

 

October 16, 2013

 

		RE:	Medgenics, Inc. (the “Company”)

 

Dear Bill,

 

I am writing to you on behalf of the board of directors of the
Company to confirm arrangements with regard to the terms of appointment to office as a director of the Company from the date of
this letter.

 

		1	Definitions

 

For the purposes of this Letter, the following words or expressions
shall have the following meanings respectively:

 

		“AIM”	means the AIM Market of London Stock Exchange
plc;

 

		“Biopump”	means a micro organ which has undergone ex-vivo transduction
with a vector such that it produces and secretes a desired therapeutic protein;

 

		“Board”	means the board of directors of the Company, including
any committee of the Board duly constituted by it;

 

		“Businesses”	means:

 

		(a)	the business of the research, development, design, production,
manufacturing, marketing, sale, distribution and other commercial activities of any Group Company in relation to the Group’s
proprietary and/or licensed technology concerning a platform technology for the treatment of various
diseases and/or chronic disorders and conditions whereby a sliver of human dermal tissue is converted
into an internal protein production plant, through ex vivo transduction with a viral or non-viral vector, and the processed
tissue is re-implanted under the human donor’s skin to provide therapeutic levels of protein delivery; and

 

		(b)	any other business that any Group Company shall at the relevant date;

 

		(i)	be engaged in and with which you shall have been concerned
or involved to any material extent at any time during Your Appointment; or

 

		(ii)	have determined to carry on with a view to developing any other biotechnical technology for commercial exploitation in the
future and in relation to which determination you shall at the Termination Date possess any material Confidential Business Information;

 

		“Confidential Business
Information”	means all and any Corporate Information, Marketing Information,
Technical Information and other information (whether or not recorded in documentary form or on computer disk or tape) which the
Company or any Group Company treats as confidential or in respect of which it owes an obligation of confidentiality to any third
party, which is not in the public domain:

 

    	 

    	 

    

 

		(a)	which you shall have acquired or shall hereafter acquire at any time during Your Appointment but which does not form part of
your own stock in trade; and

 

		(b)	which is not readily ascertainable to persons not connected with the Company or any Group Company;

 

		“Corporate Information”	means all and any information (whether
or not recorded in documentary form or on computer disk or tape) relating to the business methods, corporate plans, management
systems, finances, maturing new business opportunities or research and development projects of the Company or any Group Company;

 

		“DGCL”	means Delaware General Corporation Law;

 

		“Group”	means
the Company and its affiliates, including any company that controls, is controlled by, or is under common control with
the Company, as defined in Rule 3b-18 of the Securities Exchange Act of 1934, as amended from time to time, including, without
limitation to the generality of the foregoing, Medgenics Medical (Israel) Limited;

 

		“Group Company”	means a
member of the Group and “Group Companies” shall be interpreted accordingly;

 

		“Marketing Information”	means all and any information (whether
or not recorded in documentary form or on computer disk or tape) relating to the marketing or sales of any past present or future
product or service of the Company or any Group Company including, without limitation, sales targets and statistics, market share
and pricing statistics, marketing surveys and plans, market research reports, sales techniques, price lists, discount structures,
advertising and promotional material, the names, addresses, telephone numbers, contact names and identities of customers and potential
customers of and suppliers and potential suppliers to the Company or any Group Company, the nature of their business operations,
their requirements for any product or service sold to or purchased by the Company or any Group Company and all confidential aspects
of their business relationship with the Company or any Group Company;

 

		“Material Interest”	means:

 

		(a)	the holding of any position as director, officer, employee, consultant, partner, principal or agent;

 

		(b)	the direct or indirect control or ownership (whether jointly or alone) of any shares (or any voting rights attached to them)
or debentures save for the ownership for investment purposes only of not more than five percent (5%) of the issued shares of any
company whose shares are listed on any national securities exchange (as defined in Section 3(a)(1) of the Securities Exchange Act
of 1934, as amended from time to time), or any similar exchange in jurisdictions outside the United States, including AIM; or

 

		(c)	the direct or indirect provision of any finance;

 

other than on behalf of any Group Company for the
legitimate purposes of that Group Company;

 

		“Technical Information”	means all and any trade secrets, secret
formulae, processes, inventions, designs, know-how discoveries, technical specifications and other technical information (whether
or not recorded in documentary form or on computer disk or tape) relating to the creation, production or supply of any past, present
or future product or service of the Company or any Group Company;

 

    	 

    	 

    

 

		“Termination Date”	means the date of the termination of Your
Appointment; and

 

		“Your Appointment”	means your appointment to and holding of
office as a director of the Company as confirmed by this letter.

 

		2	Duties

 

		2.1	As a director of the Company you will be expected to exercise
the general fiduciary duties and duties of care and loyalty as provided under the DGCL and provide such advice and services as
the Board may reasonably require.

 

		2.2	The Board as a whole is collectively responsible for the
success of the Company. The Board’s role is to:

 

		2.2.1	provide entrepreneurial leadership of the Company within
a framework of prudent and effective controls, which enable risk to be assessed and managed;

 

		2.2.2	set the Group’s strategic aims, ensure that the
necessary financial and human resources are in place for the Company to meet its objectives and review management performance;
and

 

		2.2.3	set the Company’s values and standards and ensure
that its obligations to its shareholders and others are understood and met.

 

		2.3	In your role as a non-executive director, you shall be
required to:

 

		2.3.1	constructively challenge and contribute to the development
of the Group’s strategy;

 

		2.3.2	scrutinize the performance of management in meeting
agreed goals and objectives and monitor the reporting of performance;

 

		2.3.3	satisfy yourself that financial information is accurate
and that financial controls and systems of risk management are appropriate, robust and defensible;

 

		2.3.4	endeavor to attend all meetings of the Board and the
annual and all other meetings of the shareholders of the Company;

 

		2.3.5	at all times comply with the certificate of incorporation
and bylaws of the Company, each as the same may be amended or restated from time to time;

 

		2.3.6	abide by your fiduciary duties as a director of the
Company;

 

		2.3.7	diligently perform your duties;

 

		2.3.8	immediately report your own wrongdoing or the wrongdoing
or proposed wrongdoing of any other employee or director of the Company of which you become aware to the Chairman of the Company;
and

 

		2.3.9	comply with the terms of the Code of Business Conduct
and Ethics adopted by the Board (a copy of which is annexed hereto) and any other code of practice issued by the Company from
time to time relating to dealing in the Company’s securities.

 

		2.4	In addition, your duties shall require that you shall:

 

		2.4.1	promote the highest standards of integrity, probity
and corporate governance throughout the Company, particularly at Board level;

 

		2.4.2	use your best endeavors to ensure that the Board receives
accurate, timely and clear information;

 

		2.4.3	use your best endeavors to ensure effective communication
with shareholders;

 

		2.4.4	use your best endeavors to facilitate the effective
contribution of non-executive directors and to ensure constructive relations are maintained between the executive and non-executive
directors;

 

		2.4.5	ensure that the performance of the Chief Executive Officer
(and of any other executive director(s) from time to time) is evaluated at least once a year; and

 

    	 

    	 

    

 

		2.4.6	at the request of the Company, serve on committees of
the Board as shall be agreed between you and the Chairman of the Company.

 

		3	Time Commitment

 

You shall work such hours per week over the term Your Appointment
as are necessary for the proper performance of your duties as a non-executive director of the Company.

 

		4	FEES

 

You will be entitled to certain cash fees in connection with
your services as set forth below:

 

	i.	Annual retainer fee	$ 15,000
	ii.	Per Board or Committee Meeting fee (including telephonic) (varies depending on location and type)	$  1,000 – $2,500
	iii.	Annual retainer fee for director acting as Chairman of committee (per committee)	$  5,000

 

The annual retainer fees are paid on a fiscal year basis and
shall be prorated for any partial year of Board service. The fees and the terms prescribing the frequency of payment are subject
to change upon the determined of the Compensation Committee of the Board. On termination of your Appointment you will (if applicable)
be paid your director’s fee on a pro-rata basis, to the extent unpaid up to the Termination Date.

 

You will receive stock options to acquire 300,000 shares of
common stock upon Your Appointment. Such options will be issued under the Company’s Stock Incentive Plan, as amended (the
“Stock Plan”), and will vest in three equal installments, with the first 100,000 options vesting upon the date of issuance,
the second 100,000 options vesting on first anniversary of the effective date of Your Appointment and the remaining options vesting
on the second anniversary of the effective date of Your Appointment, subject in each case to your continued service as a director
of the Company. You will be entitled to participate in any equity compensation program established for non-executive directors
beginning in 2014. Currently, the Company has established a plan to make annual restricted share and option grants under the Stock
Plan to be made on January 2nd of each year (or on the first business day thereafter or (as applicable) as soon as practical
thereafter when the Company is not in a close period) as follows (i) 7,000 shares of restricted stock with 50% vesting one day
after grant and the remaining 50% vesting on the first anniversary of grant; and (ii) options to purchase 15,000 shares, having
a 10 year term and vesting in equal installments over 3 years. You acknowledge that the Company may determine to change this equity
compensation program and this Letter shall in no way be deemed to be a guarantee of future option grants.

 

		5	Term of office

 

Your Appointment commenced on the date of this Letter and shall
continue following the date of this Letter unless or until your successor is elected and qualified or until your earlier resignation
or removal. You agree that you will give not less than sixty (60) days’ (or such lesser period if agreed by the Board) prior
notice in writing to the Company in the event you wish to resign prior to the expiration of your term or in the event you do not
wish to stand for re-election at the Company’s annual meeting of stockholders.

 

For the avoidance of doubt, by your
counter-signature hereto, you acknowledge that your continuation in office is subject to the DGCL and the certificate of
incorporation and bylaws of the Company, each as the same may be amended or restated from time to time.

 

On termination
of Your Appointment for whatever reason you will promptly return to the Company all documents, records, keys, correspondence or
other items in your possession or under your control which relate in any way to the business or affairs of, or are the property
of, the Company or any Group Company and all copies thereof, regardless of the medium upon or in which such copies are stored
or held. In addition, you will cease to use the Company’s facilities and cease to hold yourself out as being a director
of the Company.

 

    	 

    	 

    

 

		6	Expenses

 

The Company shall reimburse you in respect of all reasonable
travelling, hotel, entertainment and other out of pocket expenses properly and necessarily incurred by you in or about the performance
of your duties under this Agreement, subject to the production (if requested) of any receipts, vouchers and other supporting documentation
that the Company shall reasonably require.

 

		7	Confidentiality

 

		7.1	Both during the currency and after the Termination Date,
you will treat all Confidential Business Information as confidential and not use or disclose the same to any other party except:

 

		7.1.1	insofar as may be necessary for the proper and effective
performance of your duties as a director of the Company and then only to a person who shall be subject to equivalent, express,
written confidentiality obligations to the Company or a Group Company;

 

		7.1.2	to the extent that such information is or (without default
of your part) becomes generally available to the public; or

 

		7.1.3	to the extent that you shall be required to disclose
the same by any applicable law or legally binding order of any court, government, semi-governmental authority, administrative
or judicial body, or a legally binding requirement of a stock exchange or regulator.

 

		7.2	If you are required to make a disclosure as contemplated
in clause 7.1.3:

 

		7.2.1	you must disclose only the minimum Confidential
Business Information required to comply with the applicable law, order or requirement; and

 

		7.2.2	before making such disclosure, you must:

 

		(a)	give the Company reasonable written notice of:

 

		(i)	the full circumstances of the requirement for disclosure arising; and

 

		(ii)	the Confidential Business Information which you propose to disclose; and

 

		(b)	consult with the Company as to the form of the disclosure.

 

		7.3	By your counter-signature hereto, you acknowledge that:

 

		7.3.1	the Company and each Group Company possess a valuable
body of Confidential Business Information;

 

		7.3.2	the Company has given and will continue to give you
access to Confidential Business Information in order that you may carry out your duties hereunder;

 

		7.3.3	your duties include, without limitation, a duty of care
and a duty of loyalty as provided under the DGCL; and

 

		7.3.4	the disclosure of any Confidential Business Information
other than for the legitimate business purposes of the Company or any Group Company, including (without limitation) to an actual
or potential competitor of the Company or any Group Company could place such company at a serious competitive disadvantage and
could cause immeasurable (financial and other) damage to the Businesses

 

and
that the obligations of confidentiality assumed under the provisions of this clause 7 are reasonable and necessary for the protection
of the Group, the Businesses and the Confidential Business Information.

 

		8	Other Interests and Restrictions

 

		8.1	It is accepted and acknowledged that you have business
interests other than those of the Company and that you have declared any potential conflicts that are apparent at present. If
you become aware of any potential conflicts of interest after the date hereof, these should be disclosed to the Chairman of the
Company and company secretary as soon as you become aware thereof.

 

    	 

    	 

    

 

		8.2	By your counter-signature hereto,
you agree and undertake that, during the term of Your Appointment, you shall not, without the Company’s written permission,
assume or hold any Material Interest in any person, firm or company which:

 

		8.2.1	impairs or might reasonably be thought by the Board
to impair your ability to act at all times in the best interests of the Company; or

 

		8.2.2	requires or might reasonably be thought by the Board
to require you to disclose any Confidential Business Information in order properly to discharge your duties to or to further your
interest in such person, firm or company.

 

		8.3	By your counter-signature hereto, you agree and undertake
that you will not, without the Company’s written permission, during the term of Your Appointment and for the period of 12
months after the Termination Date, in any part of the world, whether directly or indirectly:

 

		8.3.1	assume or hold a Material Interest in a business which
manufactures, distributes or utilizes the Group’s Biopump technology using Biopumps;

 

		8.3.2	solicit, or by any other means induce or seek to induce,
any person, firm or company with whom or which any Group Company transacts business (whether as customer, supplier, contractor,
licensor, adviser or otherwise in relation to the Business) to cease dealing with such Group Company or to restrict or vary the
terms upon which it deals with such Group Company;

 

		8.3.3	solicit or entice away or employ or engage or seek to
entice away from any Group Company any person who is and was at the Termination Date or at any time during the six (6) months
prior to the Termination Date a director, scientific adviser, regulatory adviser, bioscience engineer or other scientific, program,
product development, marketing, sales, licensing, research and development and/or other senior manager, key salesperson or secretary
(if any) assigned to you; and

 

		8.3.4	enter into a license with Yissum Research Development
Company of the Hebrew University of Jerusalem (“Yissum”) for any of the technologies that are currently expressly
excluded from the “Scope” of the Agreement between Yissum and the Company dated November 23, 2005 (the “Yissum
License”), as set forth on Appendix A of the Yissum License.

 

		8.4	By your counter-signature hereto, you agree and undertake
that you will not at any time after the Termination Date, represent or hold yourself out or permit yourself to be represented
or held out by any person, firm or company as being in any way then currently connected with or interested in the Company or any
Group Company other than (if such be the case) as the holder of shares, options and/or warrants in the Company.

 

		8.5	Each of the provisions of clauses 8.2, 8.3 and 8.4 and
(where applicable) the sub-clauses thereof is independent and severable from the remaining provisions and enforceable accordingly.
If any provision of the said clauses/sub-clauses shall be unenforceable for any reason but would be enforceable if part of the
wording thereof were deleted, it shall apply with such deletions as may be necessary to make it enforceable.

 

		8.6	You have given the undertakings contained in this clause
8 to the Company itself and to the Company as trustee for the benefit of each Group Company and will, at the request and cost
of the Company, promptly enter into direct undertakings with any Group Company which correspond to the undertakings in this clause
8.

 

		8.7	The Company agrees that each Material Interest that you
assume or hold as of the date hereof is hereby permitted.

 

    	 

    	 

    

 

		9	Independent Legal Advice

 

Occasions may arise when you consider that
you will need professional advice in connection with the performance of your duties as a director of the Company and you will be
able to consult the Company’s advisors for this purpose. Exceptional circumstances may occur when it may be appropriate for
you to seek such advice from independent advisors, at the Company’s expense. In such an event, you should, where reasonably
practical and not (in your reasonable judgment) prejudicial to the interests of the Company, consult with the Board or, if you
consider appropriate, the non-executive directors, prior to such advice being sought or expense being incurred.

 

		10	Governing law and jurisdiction

 

This Letter shall be governed by and shall be interpreted in
accordance with the DGCL. The parties irrevocably submit to the non-exclusive jurisdiction of the state courts of Delaware, USA
in relation to all matters arising out of or in connection with this appointment letter.

 

On a more personal note, I want to tell you how pleased I am
that you are joining the Medgenics Board of Directors. I know that I speak for the other directors in saying that we look forward
to your leadership and contributions as a director. As required by AIM rules, I should be grateful if you would please confirm
your acceptance of the terms of your appointment by signing and returning the duplicate of this Letter.

 

With kind regards,

 

 

/s/ Sol J. Barer

 

Sol J. Barer, Ph.D.

Duly authorized for and on behalf of the Board

 

 

I hereby acknowledge the above terms and agree and undertake
in the above terms.

 

 

	SIGNED AS A DEED	)	 	 	 
	by Wilbur H. Gantz	)	 	 	 
	in the presence of:-	)	 	/s/ Wilbur H. Gantz	 
	 	 	 	Wilbur H. Gantz	 
	 	 	 	 	 
	 	 	 	 	 
	Witness Signature:	 	.
	Name:	 	 
	Address:	 	 
	 	 	..
	 	 	..
	Occupation:	 	.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]